NICE Supports Amgen’s Melanoma Therapy Imlygic

The UK’s drug pricing watchdog has recommended that the National Health Service reimburse for Amgen’s melanoma therapy Imlygic, provided that the company lowers the price.

In a final appraisal, the National Institute for Health and Care Excellence deemed the new therapy a valuable option for patients due to its novel mechanism of action. Unlike other treatments, Imlygic achieves local tumor control and triggers a systemic anti-tumor immune response.  

In clinical trials, Imlygic showed a statistically significant improvement of 25.3 months in overall survival for patients who are not suited for immunotherapies and have melanoma that has not spread to the bone, brain, lungs or other internal organs.